✓ Translated by DotMD AI Clinical Council
Source: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #38323492 ↗
What the Study Found (In Plain English)
Published in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024), this phase iii randomized trial evaluating human clinical outcomes investigated: Mechanisms underlying kidney benefits with sodium-glucose cotransporter-2 (SGLT2) inhibition in heart failure and/or type 2 diabetes (T2D) with established cardiovascular disease are currently unclear. Key clinical takeaway: Changes in hematocrit and hemoglobin were the strongest mediators of empagliflozin's kidney benefits in EMPA-REG OUTCOME participants with T2D and cardiovascular disease.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2024-08-30; Phase III Randomized Trial; Rigor 82/100): Changes in hematocrit and hemoglobin were the strongest mediators of empagliflozin's kidney benefits in EMPA-REG OUTCOME participants with T2D and cardiovascular disease.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.